^
    7d
    B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (clinicaltrials.gov)
    P1, N=48, Recruiting, St. Jude Children's Research Hospital | N=32 --> 48 | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    8d
    Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Apr 2036 | Trial primary completion date: Mar 2026 --> Apr 2036
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    9d
    BrainChild-03: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (clinicaltrials.gov)
    P1, N=90, Recruiting, Seattle Children's Hospital | Trial completion date: May 2041 --> May 2042 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    SCRI-CARB7H3(s)
    22d
    RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs. (PubMed, J Immunother Cancer)
    Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells. Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    1m
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jun 2028 --> Apr 2030 | Trial primary completion date: Jun 2026 --> Apr 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CAR.B7-H3 T
    1m
    Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03. (PubMed, Neurooncol Pract)
    This study retrospectively applies TIAN criteria to patients with DIPG/pontine DMG treated with intraventricular B7-H3 CAR T cells in the BrainChild-03 (BC-03) trial (NCT04185038)...TIAN was common within this cohort but mostly low-grade and transient. Refining its classification and understanding its clinical impact will aid safety assessments and trial comparisons for CNS-directed CAR T therapies.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    2ms
    Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, Chulalongkorn University | Trial primary completion date: Dec 2026 --> Dec 2027 | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule) • IL7R (Interleukin 7 Receptor)
    2ms
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    3ms
    Study of Intracerebroventricular MT027 in Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, T-MAXIMUM Pharmaceutical Inc
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
    |
    MT027
    3ms
    A Phase I Dose-Escalation and Dose-Expansion Clinical Study Evaluating the Tolerability, Safety, Pharmacokinetics , and Efficacy of MT027 Cell Injection in Patients with Triple-Negative Breast Cancer and Brain Metastases (ChiCTR2600116792)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule)
    |
    ER negative
    |
    MT027
    3ms
    A Dose-escalation and Dose-expansion Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile, and Efficacy of MT027 Cell Injection in Patients with Lung Cancer Complicated by Brain and/or Leptomeningeal Metastases (ChiCTR2600116919)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    MT027
    5ms
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T